In case you haven’t seen it, a 2007 model suggests that turnover rates have a complex relationship with cancer and aging. Mutations during cell division would tend to make high turnover rates cause both aging and cancer. Mutations that are caused by DNA damage independently of cell division tend to make high turnover rates protective against aging, but cancer-promoting. I’ve only looked at the abstract so far. If that aspect of the turnover/mutation relationship holds and turns out to be the most important way turnover relates to aging, then it becomes hard to say intuitively whether cell turnover is on net protective or promoting of aging.
Some questions I have before a deeper dive into the paper:
Does the model address the function of turnover in selecting against internally disorganized cells?
Does the model address mechanisms that select against dysfunctionally mutated cells?
Does the model address disorder introduced by imprecise replacement of the old cells, either in terms of the organization or the location of the replacement cell?
In case you haven’t seen it, a 2007 model suggests that turnover rates have a complex relationship with cancer and aging. Mutations during cell division would tend to make high turnover rates cause both aging and cancer. Mutations that are caused by DNA damage independently of cell division tend to make high turnover rates protective against aging, but cancer-promoting. I’ve only looked at the abstract so far. If that aspect of the turnover/mutation relationship holds and turns out to be the most important way turnover relates to aging, then it becomes hard to say intuitively whether cell turnover is on net protective or promoting of aging.
Some questions I have before a deeper dive into the paper:
Does the model address the function of turnover in selecting against internally disorganized cells?
Does the model address mechanisms that select against dysfunctionally mutated cells?
Does the model address disorder introduced by imprecise replacement of the old cells, either in terms of the organization or the location of the replacement cell?